MAPT and Alzheimer disease: Higher CSF tau and p-Tau levels have been associated with worse cognitive performance at the AD dementia stage [35,36], but in our sample blood, NDEV p181-Tau was associated with better performance on Digit Span Backward and Trails B. A benefit of measuring AD-related biomarkers in NDEVs compared to plasma is improved overall detectability, especially in controls.